Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TNX-2130

Other · developed by Tonix Pharmaceuticals

Phase 1 Most advanced trial (none active)
TNXP Developer
1 Registered trials

What is TNX-2130?

TNX-2130 is a preparation of non-spike SARS-CoV-2 proteins administered intradermally. It is studied for detecting delayed-type hypersensitivity reactions in individuals exposed to SARS-CoV-2.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
Tonix Pharmaceuticals, Inc. (TNXP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05216510 Phase 1 Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… Terminated TNXP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

More from Tonix Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TNXP page.

Follow TNXP, the company behind TNX-2130

See TNXP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TNXP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.